Compare Sanofi SA (SNY) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Western Union Co — how do they compare? Sanofi SA trades at $43.6 (market cap $104.30B), while Western Union Co trades at $7.1 (market cap $2.20B). The key difference: Sanofi SA is far larger — about 47.4× Western Union Co's market cap, and Western Union Co pays the higher dividend (13.33%). Which is the better fit depends on your goals.
| SNY | WU | |
|---|---|---|
Market Cap | $104.30B | $2.20B |
Sector | Health | Technology |
52-Week High | $52.34 | $10.28 |
52-Week Low | $41.33 | $6.36 |
Enterprise Value | $124.19B | $2.10B |
Dividend Yield | 5.55% | 13.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Western Union (WU) trades at $7.13, up 1.42% with bearish technical signals and mixed fundamentals. The stock shows attractive valuation metrics with P/E of 5.69 and P/S of 0.56, but faces revenue decline from $4.5B in 2022 to $4.05B in 2025. Recent Q2 2026 earnings missed estimates at $0.31 vs. $0.42 expected, continuing a trend of earnings underperformance despite strong profitability margins.
The outlook remains challenging with declining revenue trends and bearish analyst sentiment (57% Hold, 31% Sell). Key risks include competitive pressure in money transfer services and digital transition challenges. The consensus price target of $7.14 offers minimal upside potential from current levels, suggesting limited near-term growth prospects for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
